Parvovirus B19 infections in paediatric sickle cell disease patients: Genotype and hydroxyurea treatment influence disease severity
British Journal of Haematology · 2026
DOI: 10.1111/bjh.70809 ↗Kurz gefasst
Fachartikel in der Zeitschrift British Journal of Haematology, 2026. Verfasst von Matthias Bleeke und 42 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pediatric Hematology and Oncology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany. Hauptthemen laut MEDLINE: Anemia, Sickle Cell, Hydroxyurea, Parvovirus B19, Human, Parvoviridae Infections. Die Arbeit nennt 27 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
In patients with sickle cell disease (SCD), parvovirus B19 infection (B19V) leads to acute anaemia (aplastic crisis), but may also be associated with other serious complications. We retrospectively analysed clinical data from paediatric SCD patients with B19V infections between 2023 and 2025, including symptoms, laboratory parameters, diagnostic procedures and treatment details to detect differences between SCD genotypes (HbSS and HbS/β 0 ‐thalassaemia, i.e. HbSS/Sβ 0 , and HbSC) and to determine the effect of hydroxyurea (HU; hydroxycarbamide) treatment in HbSS/Sβ 0 patients. Ninety‐eight patients (76 HbSS/Sβ 0 , 22 HbSC) were included in the study. There were significant differences in the symptoms of infection between genotypes, with a high prevalence of back pain as well as higher C‐reactive protein and lactate dehydrogenase levels in HbSC. HbSC patients also received chest X‐ray more frequently and required longer inpatient treatment. In addition, HbSC patients showed a significantly higher rate of immunoglobulin G seroconversion at the onset of symptoms, suggesting that antibody formation influences clinical appearance. In HbSS/Sβ 0 patients, HU treatment was associated with higher haemoglobin and reduced transfusion requirements, but more frequently with neutropenia. In summary, B19V infections induce different clinical presentations depending on SCD genotypes, with HbSC patients showing a distinct phenotypic presentation. HU treatment reduces the need for transfusions in patients with HbSS/Sβ 0 .
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pediatric Hematology and Oncology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.
- Pediatric Hematology and Oncology, Saarland University Hospital and Saarland University Faculty of Medicine, Homburg, Germany.
- Department of Pediatrics, Dr. von Hauner Children's Hospital, University Hospital LMU, Munich, Germany.
- Department of Pediatric Hematology and Oncology, Children's Hospital Amsterdamer Straße, Cologne, Germany.
- Department of Pediatric Oncology, Hematology and Clinical Immunology, Medical Faculty, Heinrich Heine University Düsseldorf, Düsseldorf, Germany.
- Department of Pediatrics and Adolescent Medicine, Ulm University Medical Center, Ulm, Germany.
ORCID-Profile: Matthias Bleeke, Arne Simon, Beate Winkler, Sabine Heine, Anna Eichinger, Meinolf Siepermann, Sonya El Amouri, Arndt Borkhardt, Wolfgang Novak, Michael Dworzak, Sarah Goretzki, Henriette Rudolph, Piet E Beusker, Eckard Hamelmann, Maximilian Mauritz, Rainer Misgeld, Martina Stiefel, Daniel Ebrahimi-Fakhari, Andreas Groll, Nora Naumann-Bartsch, Olaf Beck, Solvej Heidtmann, Ulf Schulze-Sturm, Urs Mücke, Holger Cario
Zitieren
APA
Bleeke, M., Simon, A., Winkler, B., Heine, S., Eichinger, A., von Both, U., Siepermann, M., El Amouri, S., Borkhardt, A., Pritschow, Y., Novak, W., Dworzak, M., Goretzki, S., Held, C., Beutel, K., Gams, F., Rudolph, H., Koscher, L., Beusker, P. E., …, & Cario, H. (2026). Parvovirus B19 infections in paediatric sickle cell disease patients: Genotype and hydroxyurea treatment influence disease severity. British Journal of Haematology. https://doi.org/10.1111/bjh.70809
Vancouver
Bleeke M, Simon A, Winkler B, Heine S, Eichinger A, von Both U, et al. Parvovirus B19 infections in paediatric sickle cell disease patients: Genotype and hydroxyurea treatment influence disease severity. British Journal of Haematology. 2026. doi:10.1111/bjh.70809
BibTeX
@article{Bleeke2026,
author = {Bleeke, Matthias and Simon, Arne and Winkler, Beate and Heine, Sabine and Eichinger, Anna and von Both, Ulrich and Siepermann, Meinolf and El Amouri, Sonya and Borkhardt, Arndt and Pritschow, Yvonne and Novak, Wolfgang and Dworzak, Michael and Goretzki, Sarah and Held, Clara and Beutel, Karin and Gams, Franziska and Rudolph, Henriette and Koscher, Leila and Beusker, Piet E and Hamelmann, Eckard and Weichert, Stefan and Häuser, Svenja and Mauritz, Maximilian and Aydin, Malik and Wiegering, Verena and Grosse, Regine and Misgeld, Rainer and Stiefel, Martina and Töpfner, Nicole and Falke, Uta and Imhof, Lara and Tagliaferri, Laura and Ebrahimi-Fakhari, Daniel and Groll, Andreas and Appel, Marion and Naumann-Bartsch, Nora and Nathrath, Michaela and Beck, Olaf and Heidtmann, Solvej and Tischer, Philipp and Schulze-Sturm, Ulf and Mücke, Urs and Cario, Holger},
title = {Parvovirus B19 infections in paediatric sickle cell disease patients: Genotype and hydroxyurea treatment influence disease severity},
journal = {British Journal of Haematology},
year = {2026},
doi = {10.1111/bjh.70809}
}
EUVIMED